Treatment with the topical JAK inhibitor reduced abscess and inflammatory nodules in a phase 2 randomized, controlled trial in patients with mild hidradenitis suppurativa.
Review found that fewer than 60% of patients with chronic inflammatory skin diseases underwent recommended testing before starting systemic immunomodulator treatment.
Across all images, diseases in darker skin types were diagnosed less accurately than diseases in lighter skin types, including when decision support from a deep learning system was introduced.
In studies with an average follow-up of 16 weeks, there was no significant increase in MACE or VTE rates in people with dermatoses treated with JAK-STAT inhibitors.
Of the 52 new drugs approved in the past decade, 21% were categorized as first in class, but more innovations are needed for skin diseases with unmet therapeutic needs, the authors said.